Publication | Open Access

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

Hematological MalignancyPediatric HematologyMedicineFlt3 Inhibitor LestaurtinibHematologyPediatricsOncologyCancer Research